HRS-4642
Unknown / undisclosed
Evidence outlook · registrational
Pancreatic Cancer: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2029-04.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other KRAS G12D drugs
GFH375, INCB161734, Setidegrasib, Zoldonrasib, ARV-806 and 6 more. Compare all 12 KRAS G12D drugs
This mechanism is crowded: 11 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Pancreatic Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| HRS-4642: this drug | Phase 3 | Undisclosed | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Capecitabine | ApprovedUS marketing discontinued | Small molecule | Fluoropyrimidine (antimetabolite) | not yet graded | No reviewed efficacy summary in this indication | |
| Erlotinib | Approved | Small molecule | EGFR | Partial signal | No reviewed efficacy summary in this indication | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | not yet graded | No reviewed efficacy summary in this indication | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Atebimetinib | Phase 3 | Small molecule | MEK (MAP2K1/2) | not yet graded | No reviewed efficacy summary in this indication | |
| GFH375 | Phase 3(overall) | Small molecule | KRAS G12D | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| INCB161734 | Phase 3(overall) | Small molecule | KRAS G12D | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Setidegrasib | Phase 3(overall) | Small molecule | KRAS G12D | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Tertomotide | Phase 3 | Peptide | Telomerase (hTERT) | not yet graded | No reviewed efficacy summary in this indication | |
| Zoldonrasib | Phase 3 | Small molecule | KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| Certepetide | Phase 2 | Peptide | Alpha-v integrins and neuropilin-1 (CendR tumour-penetration pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Motixafortide | Phase 2 | Peptide | CXCR4 | not yet graded | No reviewed efficacy summary in this indication | |
| Nogapendekin Alfa Inbakicept (Anktiva) | Phase 2 | Protein / enzyme therapeutic | IL-15 superagonist | not yet graded | No reviewed efficacy summary in this indication | |
| A2B530 | Phase 1/2 | Cell therapy | CEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker) | not yet graded | No reviewed efficacy summary in this indication | |
| ARV-806 | Phase 1/2(overall) | Small molecule | KRAS G12D | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| INV-8989 | Phase 1/2(overall) | Small molecule | KRAS G12D | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| QLC1101 | Phase 1/2(overall) | Small molecule | KRAS G12D | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| TSN1611 | Phase 1/2(overall) | Small molecule | KRAS G12D | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Debecarasib | Phase 1(overall) | Small molecule | KRAS G12D | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| KRAS-Specific Autologous TCR-T Cell | Phase 1(overall) | Cell therapy | KRAS G12V presented on HLA-A*11:01 | not yet graded | No reviewed efficacy summary in this indication | |
| LT-010391 | Phase 1(overall) | Small molecule | KRAS G12D | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| RG6620 | —(overall) | Undisclosed | KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow HRS-4642 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.